HRT Financial LP, a notable shareholder in Aditxt, Inc. (NASDAQ:ADTX), has executed a series of transactions involving the biotechnology company's common stock, resulting in a complete liquidation of its direct position. According to filings submitted to the Securities and Exchange Commission, the firm engaged in both an acquisition and a disposition of ADTX shares during mid-June 2026. These movements occur within a complex corporate environment for Aditxt, which is currently undergoing significant structural and leadership changes.
The initial transaction took place on June 18, 2026, when HRT Financial LP acquired 7,340,178 shares of Aditxt common stock. The purchase was executed at a price of $0.013 per share, resulting in a total investment of approximately $95,422. Following this acquisition, the firm's direct holdings stood at 2,406,438 shares. This purchase activity is particularly notable given the extreme volatility characterizing ADTX's recent trading history. Despite the stock trading at just $0.01 at the time of reporting, the security had posted a 116% return over the preceding week, highlighting significant price fluctuations that may influence shareholder behavior.
However, the firm's position was short-lived. On June 22, 2026, HRT Financial LP disposed of 5,120,480 shares of Aditxt common stock. These shares were sold at a price of $0.018 per share, generating total proceeds of approximately $92,168. After this subsequent sale, HRT Financial LP's direct ownership in Aditxt, Inc. stood at zero shares. The reporting owner indicated that it is not subject to Section 16 of the Securities Exchange Act of 1934, a detail that may influence the regulatory context of these transactions. HRT Financial LP is identified as a ten percent owner of Aditxt, Inc., suggesting that despite the liquidation of direct shares, the firm may retain influence or holdings through other vehicles.
Aditxt's corporate landscape is simultaneously undergoing a period of strategic financial and leadership restructuring. The company announced that its subsidiary, Ignite Proteomics LLC, will go public through a special purpose acquisition company (SPAC) deal. This transaction is expected to value Ignite at approximately $150 million. Concurrently, Aditxt appointed Jeffrey M. Busch as interim CEO. Busch continues to lead Ignite Proteomics, indicating a dual leadership structure during this transition period. Additionally, the company is set to implement a 1-for-27 reverse stock split, effective May 18, 2026, following approval by stockholders. This move is typically associated with efforts to meet exchange listing requirements.
Financially, Aditxt has taken steps to stabilize its position. The company disclosed a $1.25 million private placement of senior unsecured promissory notes. These notes carry a 10% annual interest rate and have a maturity date of September 30, 2026. The terms of the notes require that proceeds from specific stock sales be used to redeem the debt. Furthermore, Aditxt has regained compliance with Nasdaq’s listing standards. This compliance was achieved following an increase in stockholders’ equity to $3,953,682, as reported in their Annual Report. Despite these regulatory and structural improvements, broader financial health assessments remain cautious. InvestingPro assigns the company a "WEAK" financial health score, citing ongoing concerns around cash burn and liquidity.